Opendata, web and dolomites

NeutroCure SIGNED

Development of “smart” amplifiers of reactive oxygen species specific to aberrant polymorphonuclear neutrophils for treatment of inflammatory and autoimmune diseases, cancer and myeloablation.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NeutroCure project word cloud

Explore the words cloud of the NeutroCure project. It provides you a very rough idea of what is the project "NeutroCure" about.

phenotype    regulation    paradox    damaging    cells    patient    modulation    neutrophil    solution    oxygen    cure    relieve    organism    space    healthy    commercialization    reactive    haematopoiesis    previously    temporal    functions    unexplored    treatment    cell    realized    possibilities    aberrant    deactivation    resolution    breakthrough    generation    cancer    severe    leads    pharmaceutical    neutrophils    clinical    drugs    solutions    inflammation    pathological    attempt    normal    proximal    amplifiers    precise    society    trigger    tissues    contributes    mechanisms    traps    boosting    spatial    species    occurs    activation    consists    redox    nature    drug    extracellular    sme    killing    pathologic    safe    despite    abnormal    neutrocure    inhibits    caused    radio    concentration    prodrug    reverse    ros    dysregulated    myeloablation    causes    innovative    chemotherapy    disturbance    first    polymorphonuclear    positive    uncontrolled    signaling    multiple    time    nets    autoimmunity    academic    settings   

Project "NeutroCure" data sheet

The following table provides information about the project.

Coordinator
FRIEDRICH-ALEXANDER-UNIVERSITAET ERLANGEN NUERNBERG 

Organization address
address: SCHLOSSPLATZ 4
city: ERLANGEN
postcode: 91054
website: www.uni-erlangen.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 2˙999˙998 €
 EC max contribution 2˙999˙998 € (100%)
 Programme 1. H2020-EU.1.2.1. (FET Open)
 Code Call H2020-FETOPEN-2018-2019-2020-01
 Funding Scheme RIA
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2024-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FRIEDRICH-ALEXANDER-UNIVERSITAET ERLANGEN NUERNBERG DE (ERLANGEN) coordinator 629˙000.00
2    UNIVERSITATSKLINIKUM ERLANGEN DE (ERLANGEN) participant 640˙000.00
3    UNIVERSITY OF SURREY UK (GUILDFORD) participant 410˙998.00
4    CENTRO NACIONAL DE INVESTIGACIONESCARDIOVASCULARES CARLOS III (F.S.P.) ES (MADRID) participant 400˙000.00
5    LVIVSKYI NATIONALNYI MEDYCHNYI UNIVERSYTET IMENI DANYLA HALYTSKOHO UA (LVIV) participant 400˙000.00
6    REDOXIS AB SE (LUND) participant 400˙000.00
7    INSTITUT GUSTAVE ROUSSY FR (VILLEJUIF) participant 120˙000.00

Map

 Project objective

Reactive oxygen species (ROS) have key functions in healthy organism such as redox signaling for regulation of cell growth, triggering formation of neutrophil extracellular traps (NETs), and modulation of inflammation. Since in high concentration ROS are damaging to tissues, nature has evolved precise mechanisms to control their generation at the required time, concentration and space, proximal to their target. Disturbance of these mechanisms leads to aberrant ROS production that causes uncontrolled inflammation, occurs in myeloablation caused by radio- or chemotherapy and is a crucial feature of cancer cell phenotype as well as autoimmunity. Despite the damaging properties of ROS it is a paradox that pharmaceutical ROS amplifiers can reverse (“cure”) many pathologic features. For example, ROS-induced cancer cell killing inhibits cancer growth, ROS-induced deactivation of T-cells and NETs generation contributes to resolution of inflammation, and ROS-induced boosting of haematopoiesis can relieve myeloablation. These exciting possibilities have not been realized in clinical settings yet, since the high level of temporal and spatial control of ROS generation, required to allow for safe patient treatment, has yet not been achieved for any known drug. NeutroCure will be the first attempt to achieve a breakthrough solution to this problem. Using an innovative approach based on the multiple-trigger prodrug activation, this consortium will develop safe ROS amplifiers capable of boosting ROS specifically in abnormal polymorphonuclear neutrophils associated with cancer, uncontrolled inflammation and relevant for myeloablation without affecting normal cells. NeutroCure consists of 6 European academic partners and an SME who will promote commercialization of the new drugs. We expect that this project will have a great positive impact on the Society by providing previously unexplored treatment solutions for severe pathological conditions caused by dysregulated ROS-production.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NEUTROCURE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NEUTROCURE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.2.1.)

BRIEFING (2018)

Bridging the FET Innovation Gap

Read More  

ph-coding (2019)

Predictive Haptic COding Devices In Next Generation interfaces

Read More  

RSENSE (2020)

Revolutionizing disease and environmental detection with portable optoacoustic sensing

Read More